Medicenna to Engage Investors at February 2025 Conferences

Medicenna Therapeutics Corp ( (TSE:MDNA) ) has shared an update.

Medicenna Therapeutics Corp announced its participation in two key investor conferences in February 2025, where it seeks to engage with investors through presentations and one-on-one meetings. This strategic move aims to elevate the company’s visibility and strengthen its position in the biotechnology sector by showcasing their innovative immunotherapy developments.

More about Medicenna Therapeutics Corp

Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focusing on the development of Superkines for treating cancer, inflammatory, and autoimmune diseases. Their products include novel IL-2, IL-4, and IL-13 Superkines, with leading candidates such as MDNA11, a next-generation IL-2 Superkine, and bizaxofusp, an IL-4 Empowered Superkine with FDA FastTrack and Orphan Drug status.

YTD Price Performance: -20.75%

Average Trading Volume: 83,165

Technical Sentiment Consensus Rating: Buy

Current Market Cap: C$99.33M

For an in-depth examination of MDNA stock, go to TipRanks’ Stock Analysis page.